Incyte upgraded by Wells Fargo with a new price target
$INCY
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Wells Fargo upgraded Incyte from Equal Weight to Overweight and set a new price target of $89.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2025 | $89.00 | Equal Weight → Overweight | Wells Fargo |
| 8/1/2025 | $90.00 | Overweight | Barclays |
| 6/16/2025 | $107.00 | Hold → Buy | Stifel |
| 3/18/2025 | Buy → Neutral | Guggenheim | |
| 3/18/2025 | Outperform → Mkt Perform | William Blair | |
| 12/17/2024 | $77.00 | Neutral | UBS |
| 10/29/2024 | $68.00 → $90.00 | Neutral → Buy | BofA Securities |
| 10/1/2024 | $84.00 | Outperform | Wolfe Research |
144 - INCYTE CORP (0000879169) (Subject)
8-K - INCYTE CORP (0000879169) (Filer)
10-Q - INCYTE CORP (0000879169) (Filer)
Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling
Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy
Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
4 - INCYTE CORP (0000879169) (Issuer)
3 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
Wells Fargo upgraded Incyte from Equal Weight to Overweight and set a new price target of $89.00
Barclays initiated coverage of Incyte with a rating of Overweight and set a new price target of $90.00
Stifel upgraded Incyte from Hold to Buy and set a new price target of $107.00
Incyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of September: Cantor Global Healthcare Conference on Wednesday, September 3, 2025 at 8:00 am (EDT) Well Fargo Healthcare Conference on Thursday, September 4, 2025 at 8:45 am (EDT) Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 10:00 am (EDT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs.
- Company initiates search for successor and reaffirms full year financial guidance Incyte (NASDAQ:INCY) today announced that Christiana Stamoulis will step down from her role as Executive Vice President and Chief Financial Officer (CFO) to pursue another opportunity, effective September 16, 2025. Ms. Stamoulis will remain with the Company until then to support a smooth transition. The Company has initiated the process of appointing a successor. "Since joining Incyte in 2019, Christiana has been an invaluable part of the leadership team. I would like to take this opportunity to thank Christiana for her many contributions, and wish her well in her future endeavors," said Bill Meury, Pres
MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX:GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing relationship and amended its agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute retifanlimab (sold as ZYNYZ® in the United States and Europe) and axatilimab (sold as NIKTIMVO™ in the United States) in Latin America. Under the terms of the amended agreement Incyte will be responsible for the development, manufacture and supply to Knight of retifanlimab and axatilimab, and Knight will be responsible for
- Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO - Hervé Hoppenot to retire after 11 years of leading Incyte through major expansion - Julian Baker elected Chairman of the Board of Directors Incyte (NASDAQ:INCY) today announced that the Company's Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors, effective immediately. Bill Meury succeeds Hervé Hoppenot who will retire from the Company after 11 years of service. Mr. Hoppenot will serve as an advisor to the CEO and will remain as a
Mechelen, Belgium; 12 June 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director. Dr. Schaffert replaces Dr. Rajesh Parekh who stepped down on 10 June 2023. After an extraordinary 27-year career at Novartis in various global roles, including commercialization, market access, investor relations, business development & licensing, acquisitions and company integration, Dr. Schaffert retired in 2022 as President of Novartis Oncology and Member of the Novartis Executive Committee. In that role, Dr. Schaffert ran a global $15 billion business acr
Incyte (NASDAQ:INCY) announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors. "On behalf of the Incyte Board of Directors, I am happy to welcome Susanne. Her extensive commercial, development and industry experience will greatly complement our Board and we look forward to Susanne's contributions to our continued growth and future success," said Hervé Hoppenot, Chief Executive Officer, Incyte. "I am very excited for the opportunity to join the Incyte Board of Directors and helping the organization in its commitment to leading scientific innovation and developing new medicines for patients in need. I look forward to being part of this dynamic Company
SC 13G - INCYTE CORP (0000879169) (Subject)
SC 13D/A - INCYTE CORP (0000879169) (Subject)
SC 13D/A - INCYTE CORP (0000879169) (Subject)
– Total revenues of $1,216 million in the second quarter (Q2'25) (+16% Y/Y); total product revenues of $1,059 million in Q2'25 (+17%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $764 million in Q2'25 (+8% Y/Y); raising full year 2025 guidance to a new range of $3,000 - $3,050 million [previously $2,950 - $3,000 million] – Opzelura® (ruxolitinib) cream net product revenues of $164 million in Q2'25 (+35% Y/Y) – Niktimvo™ (axatilimab-csfr) net product revenues of $36 million in the second quarter, demonstrating strong commercial execution; raising full year 2025 Other Oncology guidance to a new range of $500 - $520 million [previously $415 - $455 million] – Zynyz® (retifanlimab-
Incyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13754581 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-6
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic response with the majority (82%) realizing a complete response A reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic response Initial results demonstrate a favorable safety profile – no dose limiting toxicit